Bliss GVS Pharma hits 52-week high on WHO approval and strong earnings

3 Jun 2026via India InfolineSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Bliss GVS Pharma hits 52-week high on WHO approval and strong earnings — Shares of Bliss GVS Pharma surged to a 52-week high of ₹447 following WHO's approval of its manufacturing facility. The stock rallied on the back of strong quarterly earnings and positive sentiment from a recent acquisition. Investors are optimistic about expanded global market access and future revenue growth.
📊 STOCKS: BLISSGVS | 🏢 SECTOR: Pharma | #HIGHIMPACT #Pharma

#Pharma#Earnings#Regulation#Acquisition

Stocks mentioned

BLISSGVSBliss GVS Pharma Ltd

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →